Advertisement
Home 2018

Yearly Archives: 2018

Rising drug spending in the United States is being fueled by expensive name-brand prescription medicines

Name-Brand Medications Driving Spike in U.S. Drug Spending

0
Greatest costs for Humira, Remicade, Enbrel, Novolog, and Neulasta

American Heart Association, Nov. 10-12

0
The American Heart Association 2018 Scientific Sessions The annual meeting of the American Heart Association was held from Nov. 10 to 12 in...
Patients with uncomplicated appendicitis undergoing nonoperative management are more likely to have an appendicitis-associated readmission and to develop an abscess

Harms ID’d With Nonoperative Management of Appendicitis

0
Higher likelihood of readmission, developing abscess; more follow-up needed in year after admission
Coverage for adult obesity care improved substantially in Medicaid and state employee insurance programs between 2009 and 2017

Insurance Coverage for Adult Obesity Care Increasing

0
Findings among Medicaid, state employee health insurance programs in 2009 to 2017
More than one-third of Americans have prediabetes

CDC: Many Americans May Have Prediabetes and Not Know It

0
AMA, CDC launch a campaign to raise awareness about prediabetes
Low dietary carbohydrate intake is associated with increased energy expenditure during weight-loss maintenance

Low-Carbohydrate Diets Linked to Increase in Calories Burned

0
Total energy expenditure is greater for those on a low- or moderate-carb diet during weight-loss maintenance
The rate and frequency of relapse vary for patients with multiple sclerosis

Many Patients Do Not Engage Health Care Provider During MS Relapse

0
Only half of patients reported always engaging health care providers
The Amerindian Yanomami community

No Age-Related Increase in BP for Yanomami Community

0
Communities who are among least acculturated peoples in world have no increase in BP with age
For patients with diabetes mellitus with multivessel coronary disease

AHA: Lasting Benefit for CABG in Diabetes, Multivessel Disease

0
Lower all-cause mortality in CABG group versus PCI-DES group after median follow-up of 7.5 years
Combined treatment with glecaprevir and pibrentasvir is highly effective in treating chronic hepatitis C virus genotype-1 infections that failed to respond to direct-acting antiviral therapy

Option Found for Retreatment of Chronic Hep C Infection

0
Glecaprevir + pibrentasvir effective for those who previously failed direct-acting antiviral treatment